Evidence map›Paper›PMID 41201732›Full record

ReviewDiscover oncology2025

Metformin's multifaceted role in colorectal cancer: mechanisms of action and synergy with standard treatments.

Haniye Rahimi Kolour, Nastaran Bahrami, Ehsan Nazemalhosseini-Mojarad, Amir Sadeghi, Mehdi Shamsara, Nayeralsadat Fatemi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haniye Rahimi KolourBasic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nastaran BahramiDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Ehsan Nazemalhosseini-MojaradGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Amir SadeghiGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mehdi ShamsaraDepartment of Animal Biotechnology, Institute Agricultural Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. shamsa@nigeb.ac.ir.
Nayeralsadat FatemiBasic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. n_fatemi_1363@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advancements in treatment, colorectal cancer (CRC) prevalence, mortality rates, and therapeutic resistance persist as global health concerns. The review delves into metformin's multifaceted effects on molecular pathways implicated in cancer progression and resistance, including apoptosis, autophagy, epithelial-mesenchymal transition (EMT), and ATP-binding cassette (ABC) transporters. A particular focus is placed on metformin's promising role in targeting cancer stem cells (CSCs), known for their contribution to chemoresistance, metastasis, and relapse. The potential synergy of metformin with standard CRC treatments, such as chemotherapy and radiotherapy, emerges as a pivotal theme. The review underscores the importance of elucidating metformin's mechanisms of action and optimizing its utilization through further research, potentially leading to personalized, precision medicine approaches.

Indexed as

ApoptosisATP-binding cassette transportersAutophagyCancer stem cellsColorectal cancerEpithelial–mesenchymal transitionMetforminTherapeutic resistance

Identifiers

PMID41201732
PMCPMC12595195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.